LONZA TO BUILD SECOND CELL-CULTURE FACILITY IN SINGAPORE

Lonza and Singapore's Bio*One Capital have entered into a joint venture, Lonza Biologics Tuas, to build a large-scale mammalian cell-culture facility in Singapore for the manufacture of commercial biopharmaceuticals. This will be the second such facility in Singapore, and the third one globally, that Lonza has built.

Lonza and Bio*One initially formed an agreement in February to build an 80,000-liter large-scale mammalian biopharmaceutical production facility, Lonza Biologics Singapore. Genentech has an exclusive option to acquire the facility between 2007 and 2012.

Lonza Biologics Tuas will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 to 20,000 liters, inclusive of the respective purification units. Construction will begin in February 2007, and the company expects the facility to become operational in 2011.

Bio*One Capital is the biomedical investment arm of the Singapore Economic Development Board. Lonza, based in Switzerland, manufactures large and small molecules, peptides and niche biopharmaceuticals.